Multiple Myeloma, Version 5.2026

Shaji K. Kumar; Natalie S. Callander; Kehinde Adekola; Larry D. Anderson; Muhamed Baljevic; Rachid Baz; Erica Campagnaro; Caitlin Costello; Christopher D’angelo; Benjamin Derman; Srinivas Devarakonda; Noura Elsedawy; Amandeep Godara; Kelly Godby; Jens Hillengass; Leona Holmberg; Myo Htut; Carol Ann Huff; Malin Hultcrantz; Yubin Kang; Sarah Larson; Hans C. Lee; Michaela Liedtke; Thomas Martin; James Omel; Timothy J. Robinson; Aaron Rosenberg; Shayna R. Sarosiek; Mark A. Schroeder; Daniel Sherbenou; Attaya Suvannasankha; Jason Valent; Asya Nina Varshavsky-Yanovsky; Dan Vogl; Jing Christine Ye; Emily Kovach; Rashmi Kumar

doi:10.6004/jnccn.2026.0001

Multiple Myeloma, Version 5.2026

Shaji K. Kumar
, Natalie S. Callander
, Kehinde Adekola
, Larry D. Anderson
, Muhamed Baljevic
, Rachid Baz
, Erica Campagnaro
, Caitlin Costello
, Christopher D’angelo
, Benjamin Derman
, Srinivas Devarakonda
, Noura Elsedawy
, Amandeep Godara
, Kelly Godby
, Jens Hillengass
, Leona Holmberg
, Myo Htut
, Carol Ann Huff
, Malin Hultcrantz
, Yubin Kang

Sarah Larson, Hans C. Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy J. Robinson, Aaron Rosenberg, Shayna R. Sarosiek, Mark A. Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Nina Varshavsky-Yanovsky, Dan Vogl, Jing Christine Ye, Emily Kovach, Rashmi Kumar

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).

Original language	English (US)
Article number	e260001
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	24
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2026.0001
State	Published - Jan 1 2026

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2026.0001

Cite this

Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., Campagnaro, E., Costello, C., D’angelo, C., Derman, B., Devarakonda, S., Elsedawy, N., Godara, A., Godby, K., Hillengass, J., Holmberg, L., Htut, M., Huff, C. A., Hultcrantz, M., ... Kumar, R. (2026). Multiple Myeloma, Version 5.2026. JNCCN Journal of the National Comprehensive Cancer Network, 24(1), Article e260001. https://doi.org/10.6004/jnccn.2026.0001

Kumar, SK, Callander, NS, Adekola, K, Anderson, LD, Baljevic, M, Baz, R, Campagnaro, E, Costello, C, D’angelo, C, Derman, B, Devarakonda, S, Elsedawy, N, Godara, A, Godby, K, Hillengass, J, Holmberg, L, Htut, M, Huff, CA, Hultcrantz, M, Kang, Y, Larson, S, Lee, HC, Liedtke, M, Martin, T, Omel, J, Robinson, TJ, Rosenberg, A, Sarosiek, SR, Schroeder, MA, Sherbenou, D, Suvannasankha, A, Valent, J, Varshavsky-Yanovsky, AN, Vogl, D, Ye, JC, Kovach, E & Kumar, R 2026, 'Multiple Myeloma, Version 5.2026', JNCCN Journal of the National Comprehensive Cancer Network, vol. 24, no. 1, e260001. https://doi.org/10.6004/jnccn.2026.0001

@article{f7a259c67fb94eaeb0e534a2dad8e2ec,

title = "Multiple Myeloma, Version 5.2026",

abstract = "The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).",

author = "Kumar, \{Shaji K.\} and Callander, \{Natalie S.\} and Kehinde Adekola and Anderson, \{Larry D.\} and Muhamed Baljevic and Rachid Baz and Erica Campagnaro and Caitlin Costello and Christopher D{\textquoteright}angelo and Benjamin Derman and Srinivas Devarakonda and Noura Elsedawy and Amandeep Godara and Kelly Godby and Jens Hillengass and Leona Holmberg and Myo Htut and Huff, \{Carol Ann\} and Malin Hultcrantz and Yubin Kang and Sarah Larson and Lee, \{Hans C.\} and Michaela Liedtke and Thomas Martin and James Omel and Robinson, \{Timothy J.\} and Aaron Rosenberg and Sarosiek, \{Shayna R.\} and Schroeder, \{Mark A.\} and Daniel Sherbenou and Attaya Suvannasankha and Jason Valent and Varshavsky-Yanovsky, \{Asya Nina\} and Dan Vogl and Ye, \{Jing Christine\} and Emily Kovach and Rashmi Kumar",

year = "2026",

month = jan,

day = "1",

doi = "10.6004/jnccn.2026.0001",

language = "English (US)",

volume = "24",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "1",

}

TY - JOUR

T1 - Multiple Myeloma, Version 5.2026

AU - Kumar, Shaji K.

AU - Callander, Natalie S.

AU - Adekola, Kehinde

AU - Anderson, Larry D.

AU - Baljevic, Muhamed

AU - Baz, Rachid

AU - Campagnaro, Erica

AU - Costello, Caitlin

AU - D’angelo, Christopher

AU - Derman, Benjamin

AU - Devarakonda, Srinivas

AU - Elsedawy, Noura

AU - Godara, Amandeep

AU - Godby, Kelly

AU - Hillengass, Jens

AU - Holmberg, Leona

AU - Htut, Myo

AU - Huff, Carol Ann

AU - Hultcrantz, Malin

AU - Kang, Yubin

AU - Larson, Sarah

AU - Lee, Hans C.

AU - Liedtke, Michaela

AU - Martin, Thomas

AU - Omel, James

AU - Robinson, Timothy J.

AU - Rosenberg, Aaron

AU - Sarosiek, Shayna R.

AU - Schroeder, Mark A.

AU - Sherbenou, Daniel

AU - Suvannasankha, Attaya

AU - Valent, Jason

AU - Varshavsky-Yanovsky, Asya Nina

AU - Vogl, Dan

AU - Ye, Jing Christine

AU - Kovach, Emily

AU - Kumar, Rashmi

PY - 2026/1/1

Y1 - 2026/1/1

N2 - The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).

AB - The treatment landscape for multiple myeloma (MM) is evolving rapidly and includes several new options. The management must be tailored to the individual. The NCCN Guidelines for MM provide a framework to base decisions regarding diagnosis, workup, treatment, and follow-up of both newly diagnosed and previously treated relapsed/refractory MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to newly diagnosed MM (NDMM).

UR - https://www.scopus.com/pages/publications/105028878123

UR - https://www.scopus.com/pages/publications/105028878123#tab=citedBy

U2 - 10.6004/jnccn.2026.0001

DO - 10.6004/jnccn.2026.0001

M3 - Article

C2 - 41671464

AN - SCOPUS:105028878123

SN - 1540-1405

VL - 24

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

M1 - e260001

ER -

Multiple Myeloma, Version 5.2026

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this